Literature DB >> 1929956

Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease.

T Sakamoto1, T Murata, H Inomata.   

Abstract

The eyes obtained from two Japanese autopsy cases of patients with Vogt-Koyanagi-Harada disease were immunohistochemically examined. Both patients, a 63-year-old woman and a 68-year-old man, were clinically and histologically diagnosed as having Vogt-Koyanagi-Harada disease. Immunohistochemically, the choroidal infiltrate was composed predominantly of T lymphocytes with a larger proportion of helper/inducer T cells than suppressor/cytotoxic T cells and it also included activated lymphocytes expressing CD26 and CD25 antigens. Class II major histocompatibility complex was expressed in the choroidal melanocytes as well as in the endothelium of the choriocapillaris. Depositions of complement, however, were focally noticed in the choroid. Our results indicate that the cell-mediated immune process plays an important role in the development and progression of Vogt-Koyanagi-Harada disease, while choroidal melanocytes appear to play a pathogenic role in this disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929956     DOI: 10.1001/archopht.1991.01080090096030

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

Review 1.  Immunopathology of uveitis.

Authors:  C C Chan; Q Li
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

2.  The association of systemic disorders with Vogt-Koyanagi-Harada and sympathetic ophthalmia.

Authors:  Ali Al-Halafi; Hassan Al Dhibi; Issam H Hamade; Charbel T Bou Chacra; Khalid F Tabbara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-06-30       Impact factor: 3.117

Review 3.  Pathology of Vogt-Koyanagi-Harada disease.

Authors:  Narsing A Rao
Journal:  Int Ophthalmol       Date:  2007-04-14       Impact factor: 2.031

4.  Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.

Authors:  K Norose; A Yano
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

5.  Comparison of clinical characteristics in patients with Vogt-Koyanagi-Harada disease with and without anti-retinal antibodies.

Authors:  Yuki Hashimoto; Wataru Saito; Kenichi Namba; Kazuomi Mizuuchi; Daiju Iwata; Kousuke Noda; Atsuhiro Kanda; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-07       Impact factor: 3.117

6.  Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.

Authors:  Sabine Aisenbrey; Christoph Lüke; Helen D Ayertey; Salvatore Grisanti; Andreas Perniok; Richard Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

7.  Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment.

Authors:  Hiroki Kawano; Shozo Sonoda; Takehiro Yamashita; Ichiro Maruko; Tomohiro Iida; Taiji Sakamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-04       Impact factor: 3.117

8.  Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site.

Authors:  T Okada; T Sakamoto; T Ishibashi; H Inomata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-06       Impact factor: 3.117

9.  Fluorescein fundus angiographic findings in Vogt-Koyanagi-Harada syndrome.

Authors:  Lourdes Arellanes-García; Moisés Hernández-Barrios; Jans Fromow-Guerra; Pedro Cervantes-Fanning
Journal:  Int Ophthalmol       Date:  2007-01-26       Impact factor: 2.029

Review 10.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.